SCHEMBL4982244

SCHEMBL4982244

COc1ccc(N2CCCCC2)cc1CC=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.57
LMNA P02545 1/20 0.48
KDM4E B2RXH2 4/20 0.47
MAPT P10636 4/20 0.47
TDP1 Q9NUW8 3/20 0.47
ALOX15 P16050 2/20 0.47
MAPK1 P28482 2/20 0.47
HTT P42858 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 1/20 0.47
HIF1A Q16665 3/20 0.44
SLC16A3 O15427 2/20 0.44
SLC16A1 P53985 2/20 0.44
ALDH1A3 P47895 1/20 0.43
FGFR1 P11362 1/20 0.43
PTPN1 P18031 1/20 0.43
MEN1 O00255 2/20 0.42
RAB9A P51151 2/20 0.42
KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7921901 0.81 ALDH1A1 (0.50) ALDH1A1LMNAKDM4EMAPTTDP1
SCHEMBL7916967 0.77 SLC16A3 (0.50) ALDH1A1LMNAKDM4EMAPTTDP1
SCHEMBL28860292 0.76 ALDH1A1 (0.63) ALDH1A1LMNAKDM4EMAPTTDP1
SCHEMBL14215798 0.75 TMEM97 (0.53) ALDH1A1KDM4EMAPTTDP1GAA
SCHEMBL14940383 0.75 ALDH1A1 (0.97) ALDH1A1LMNAKDM4EMAPTTDP1
SCHEMBL7303075 0.74 ALDH1A1 (0.65) ALDH1A1LMNAKDM4EMAPTMAPK1
SCHEMBL12806687 0.74 ALDH1A1 (0.60) ALDH1A1LMNAKDM4EMAPTTDP1
SCHEMBL13849368 0.73 ALDH1A1 (0.55) ALDH1A1LMNAKDM4EMAPTTDP1
SCHEMBL23636917 0.73 ALDH1A1 (1.00) ALDH1A1LMNAKDM4EMAPTTDP1
SCHEMBL6065386 0.72 ALDH1A1 (0.62) ALDH1A1LMNAKDM4EMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives TPH1, HTR1D, HTR1B ALDH1A1 91/4885LMNA 3030/4885KDM4E 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.